fbpx
  • The HR Empire
Business

Biocon Launches Everolimus Tablets in the US Market

Biocon Launches Everolimus Tablets in the US Market

Biocon today announced the launch of Everolimus tablets, a generic version of Afinitor, in the US.

Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg, and 10mg, with the 10 mg tablet being a ‘day-1’ generic launch.

Everolimus (Afinitor) is a prescription medication that is used to treat certain types of cancers and tumors.
The commercial launch of Everolimus follows US FDA approval in February 2021.

Previous ArticleNext Article

Related Posts